US EPA

7148786 

Journal Article 

Standards of Care Issues With Anticoagulation in Real-World Populations 

Berger, Jan; Balfour, DC III; Biskupiak, JE; Dunn, JD; Liotta, DB; Merli, GJ; Pezalla, EJ; Shaya, FT; Villanueva, T; , 

2015 

Yes 

American Journal of Managed Care
ISSN: 1096-1860 

MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC 

PLAINSBORO 

S4-S9 

25734524 

WOS:000350971300001 

Current guidelines recommend anticoagulants for reducing the risk of stroke in appropriate patients with nonvalvular atrial fibrillation (NVAF) and for the acute treatment of venous thromboembolism (VTE) and the prevention of recurrent VTE. Warfarin is the standard of care for both NVAF and VTE, yet International Normalized Ratio (INR) control remains suboptimal, even in the clinical trial setting. Maintaining INR within the recommended therapeutic range is associated with better outcomes in these distinct populations. In VTE, high rates of recurrence have been reported during the first few weeks of treatment, emphasizing the importance of surveillance during this time and of early optimization of anticoagulation therapy. The NVAF population tends to have more comorbidities and requires longer-term therapy. It is important to keep in mind that real-world patient populations are more complex than those in controlled studies. Patients with multiple comorbidities are particularly challenging, and physicians may focus on clinically urgent issues rather than anticoagulation optimization. Despite the many complexities associated with the use of warfarin, it remains a mainstay of anticoagulation therapy. Aligning financial incentives and improving care coordination are important factors in moving toward better outcomes for patients who need anticoagulation therapy. The increased focus on value-based care and evolving approaches to patient treatment could lead more physicians and payers to consider alternatives to warfarin, including the use of novel oral anticoagulants.